Connecting patients everywhere to precision oncology

Oncomine Dx Express Test (CE-IVD)

Genomic profiling in precision oncology is transforming cancer care for your patients. But long waiting periods for biomarker test results from the laboratory can delay therapy decisions. However, now with the new Ion Torrent™ Oncomine™ Dx Express Test, laboratories will be able to:

- Generate clinically relevant biomarker results in as little as 24 hours
- Integrate molecular biomarker profiling, including EGFR, BRAF, KRAS, ERBB2, ALK, ROS1, RET, MET, and NTRK1/2/3, among others, with PD-L1 results, into one complete report
- Match biomarker results to approved therapies, guidelines, and clinical trials
- Provide results for even small samples, thereby limiting the need for re-biopsy

The Oncomine Dx Express Test is based on amplicon technology requiring the lowest sample input compared to hybrid capture–based next-generation sequencing (NGS). A recent real-world study of 31,101 patient samples demonstrated that 94.2% of the samples were successfully tested with amplicon-based technology, hence increasing access to precision oncology¹ (Figure 1).

Figure 1. Amplicon-based NGS offers best-in-class sample input requirements resulting in higher patient sample success rates¹.
The Oncomine Dx Express Test covers 100% of the clinical routine biomarkers in non-small cell lung cancer (NSCLC) and the majority of clinical routine biomarkers for other solid tumors per ESCAT* Tier 1²

The importance of timely biomarker results
In the absence of molecular data, chemotherapy and/or immunotherapy (IO) can be indicated for NSCLC patients, while some could be eligible for targeted therapy. Findings from the Integra Connect database analysis of 525 patients with stage 4 NSCLC harboring actionable oncogenic drivers suggest that treatment outcomes were significantly compromised in patients (n=141) who initiated treatment before their genomic profiling results were reported, compared to patients (n=384) who initiated treatment after receiving their genomic profiling results³ (Figures 2 and 3).

The Oncomine Dx Express Test can deliver results in as little as 24 hours, allowing the laboratory to integrate molecular biomarker results with immunohistochemistry results such as PD-L1. In a recent multicentric performance evaluation study, 6 clinical laboratories were able to generate results with the Oncomine Dx Express Test on average of 18.3 hours from nucleic acid to report⁴.

Ask your laboratory for fast NGS, so you and your patients don’t have to wait weeks for results

* ESCAT: ESMO scale for clinical actionability of molecular biomarkers,
** BRCA1/2 are not covered by the Oncomine Dx Express Test

References

For In Vitro Diagnostic Use. CE-IVD according to IVDD. Not available in all countries including the United States. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. The content provided herein may relate to products that have not been officially released and is subject to change without notice. EXT1632 0822